Prostate cancer screening now recommended for men in their 50s and 60s – lead author of new screening guidelines explains why

The American Cancer Society announced on November 12, 2026 that it had released major changes to its prostate cancer screening guidelines to improve detection and treatment of the disease.

The Conversation asked Dr. Andrew Wolf, a physician at the University of Virginia and one of the lead authors of the new guidelines, to explain to readers the changes and why they were made.

What are the new screening recommendations?

The biggest change is that we are proactively recommending prostate cancer screening. Previously, we recommended that people talk to their healthcare professional to decide whether or not screening is right for them.

Our new recommendations vary by age and risk of developing prostate cancer.

For people at average risk of developing prostate cancer, we recommend that they have a prostate-specific antigen, or PSA, blood test every two years between the ages of 50 and 69. PSA is a protein produced by prostate cells. Cancer and other conditions can cause PSA levels to rise.

People at higher risk, including black men and men with a strong family history of prostate cancer, should be screened annually between ages 45 and 69. A strong family history means that a family member was diagnosed with prostate cancer before age 65, or that multiple family members were diagnosed at any age. People who have only one family member diagnosed at age 65 or older should be screened every two years, from ages 45 to 69.

For people aged 70 to 74, we recommend that they discuss whether or not to continue screening with their healthcare professional. Given uncertainty about the benefits of screening for people in this age group, decision-making about screening depends on their personal preferences, general health, and life expectancy.

For people over 74, we do not recommend screening for prostate cancer. The potential harms of screening, such as follow-up tests and more invasive treatments, will likely outweigh the benefits for people in this age group.

Finally, we do not recommend the use of digital rectal examination to detect prostate cancer, because it is less effective than the PSA test. A digital rectal exam can still be helpful to further evaluate elevated PSA levels or prostate-related symptoms.

Close-up of a clinician tying a tourniquet around a person's arm for a blood test
Testing your PSA involves a single blood test.
Seventy-four/iStock via Getty Images

Why were the testing guidelines updated?

Over the past decade, more and more evidence has demonstrated the benefits of using the PSA blood test to screen for prostate cancer.

The PSA test’s ability to reduce the risk of death from prostate cancer or diagnosis of metastatic disease is actually greater than researchers previously thought.

At the same time, significant progress has been made to reduce potential harms associated with prostate cancer screening, including false-positive PSA test results and the diagnosis and treatment of prostate tumors that are unlikely to harm patients in the long term.

Who is most at risk for prostate cancer?

Black men have about a two-thirds higher risk of developing prostate cancer than white men. They are also at greater risk of developing more advanced disease at the time of diagnosis. These disparities are likely due to a combination of genetic, environmental, social, and access to health care factors.

Men with a family history of prostate cancer in a close relative – such as a parent, sibling or child – are also at high risk.

There are also a number of genetic mutations, such as BRCA2which confer a significantly elevated risk of prostate cancer. Although screening recommendations for these cases are beyond the scope of our guidelines, several professional medical organizations, including the National Comprehensive Cancer Network and the American Urological Association, have issued recommendations for screening individuals with these high-risk mutations.

Why is the PSA test so controversial?

For years, clinicians believed that the benefits of PSA screening were uncertain and did not necessarily outweigh the potential harms. This position is partly explained by the results of two large prostate cancer screening trials published in 2009. One, an American study, found no benefit from screening; the other, a European study, found relatively little benefit.

However, it later became clear that the US study was so flawed that it could not have shown any benefit: almost 90% of men in the control group – that is, the group who were not supposed to be tested – were actually tested, and many men with abnormal PSA levels were not followed up.

Conversely, most of the men in the European study who were randomized to receive standard care – without testing – instead of a screening test, did not actually have a PSA test. So it was more of a true comparison of the effect of screening versus no screening.

After researchers followed patients for more than two decades in the European study, the effects of screening became clear: Screening reduced the risk of dying from prostate cancer by 13 percent. And around 500 men needed to be screened to prevent death from prostate cancer.

This may not sound very impressive, but it is comparable to other commonly offered cancer screening tests, such as mammography for breast cancer. And the proportion of people needing screening to save a life would be significantly lower if extrapolated to a lifetime of screening starting at age 45 or 50, rather than the average number of two screenings men received in the study.

Why are there differences in the guidelines?

The U.S. Preventive Services Task Force also has its own guidelines for prostate cancer screening. The task force’s guidelines currently recommend that clinicians not screen for prostate cancer unless the patient indicates a preference to continue. When the task force was last updated in 2018, it determined that the potential benefits and harms of screening were too closely balanced to recommend screening.

The working group has undertaken to update these guidelines over the past several years. It is possible that their update will align more with that of the American Cancer Society.

I believe we have both sufficient evidence of benefit and sufficient risk reduction to now proactively recommend screening. Where the two guidelines align is that they both recommend that patients be informed of the benefits, risks, and limitations of prostate cancer screening so that they know what they are getting into.

It is likely that our new screening recommendations will be covered by most insurers. However, patients may have to pay out of pocket to further test their doctor’s orders due to an abnormal PSA level.

Person holding a blue ribbon
Detecting prostate cancer at an early stage increases the chances of curing it.
andreswd/E+ via Getty Images

What would you say to people who are hesitant about getting tested?

Although the benefits far outweigh the risks, there may be legitimate reasons why some people do not want to be screened.

Some people may want to avoid having to have a prostate biopsy, which allows clinicians to diagnose prostate cancer if a patient has an elevated PSA level and an abnormal follow-up MRI or biomarker test. Prostate biopsies are uncomfortable and can cause bleeding or sometimes infection.

Some people may want to avoid the need for active surveillance if they discover they have a tumor that is not growing aggressively. Active surveillance involves periodic biopsies, MRI scans, or both, which can be inconvenient and cause anxiety.

Some people may want to avoid the potential side effects of surgical or radiation treatment for early-stage prostate cancer, which can cause sexual, urinary, and bowel problems.

However, forgoing screening also means giving up the possibility of detecting cancer in its early stages, when the chances of cure are very high.

Gn Health

Logo